Related Experiment Videos

Perils with Pirfenidone and "the tuberculosis link"

Madhav H Hande1, K Vishak Acharya2, A Shreenivasa2

  • 1Department of Medicine, Kasturba Medical College, MAHE, Mangalore, Karnataka, India.

Insights

Patients with idiopathic pulmonary fibrosis (IPF) on pirfenidone may face an increased risk of developing tuberculosis (TB). A rare skin reaction, exfoliative dermatitis, occurred due to pirfenidone and rifampicin interaction.

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Dermatology

Background:

  • Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease.
  • Pirfenidone is an antifibrotic medication used to treat IPF.
  • Tuberculosis (TB) is an infectious disease primarily affecting the lungs.

Observation:

  • A patient diagnosed with IPF and treated with pirfenidone developed TB.
  • The patient later experienced exfoliative dermatitis, a severe skin reaction.
  • This dermatitis was attributed to an interaction between pirfenidone and rifampicin, an anti-TB drug.

Findings:

  • This case suggests a potential increased risk of TB in IPF patients receiving antifibrotic therapy.
  • A previously undocumented adverse drug reaction involving pirfenidone and rifampicin was observed.
  • The interaction led to severe exfoliative dermatitis.

Implications:

  • Clinicians should consider the risk of TB in IPF patients on pirfenidone.
  • Awareness of this potential drug interaction is crucial for managing co-existing TB and IPF.
  • Further investigation into pirfenidone-rifampicin interactions and associated dermatological reactions is warranted.

Related Concept Videos